Nobuaki Amino

Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade

Shinsuke Nakao, Yukinori Arai, Mamoru Tasaki et al. · Science Translational Medicine · 2020 · 175 citations

Broad spectrum and potent antitumor activities of YM155, a novel small‐molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models

Takahito Nakahara, Aya Kita, Kentaro Yamanaka et al. · Cancer Science · 2010 · 165 citations

Chemoprevention Strategy, Xenograft Models, Pharmacotherapy +21

YM-201627: An orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation

Nobuaki Amino, Yukitaka Ideyama, Mayumi Yamano et al. · Cancer Letters · 2005 · 51 citations

Selective Inhibition, Oncology, Angiogenesis +9

YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model

Nobuaki Shindoh, Masamichi Mori, Yoh Terada et al. · International Journal of Oncology · 2008 · 40 citations · Full text

Histone Modifications, Hdac Inhibitors, Antitumor Activity +17

Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma

Naoki Kaneko, Keisuke Mitsuoka, Nobuaki Amino et al. · Clinical Cancer Research · 2014 · 38 citations